Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

PARP inhibitors in metastatic breast cancer: Where are we now?

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.06.19
Views: 284

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

Prof Nadia Harbeck speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the role of PARP inhibitors in metastatic breast cancer and possibly in early breast cancer.

Since the recent approval of olarparib and talazoparib, she believes screening should ideally be carried out for every patient in the metastatic setting to identify those patients with BRCA mutations, who may receive the benefit from PARP inhibitors.

Prof Harbeck also mentions some recent data about the use of PARP inhibitors in combination with immunotherapy.

This programme has been supported by an unrestricted educational grant from Pfizer.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation